Literature DB >> 11552747

Anti-mutagenic compounds from corn.

A Burgos-Hernández1, R López-García, H Njapau, D L Park.   

Abstract

In previous studies with aflatoxin-contaminated corn an uncharacteristic response for AFB1 in the Salmonella/microsomal mutagenicity assay (Ames test) was observed and the presence of anti-aflatoxin factors in the corn was suggested. In the current study, corn was extracted and fractionated using thin layer chromatography (TLC) using different developing solvent systems and the Ames test was used to monitor for anti-mutagenic activity in the corn fractions. Both Salmonella tester strains TA98 and TA100 with metabolic activation (S9) were used. Several corn fractions, at different stages in the isolation and purification process, showed anti-mutagenic dose-responses when exposed to pure AFB1. Corti extracts were non-toxic to the tester strains and TLC fractions that showed the best anti-mutagenic dose-responses were selected for further partial characterization analyses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11552747     DOI: 10.1080/02652030119434

Source DB:  PubMed          Journal:  Food Addit Contam        ISSN: 0265-203X


  2 in total

1.  Antimutagenicity and antiproliferative studies of lipidic extracts from white shrimp (Litopenaeus vannamei).

Authors:  Griselda Wilson-Sanchez; Carolina Moreno-Félix; Carlos Velazquez; Maribel Plascencia-Jatomea; Anita Acosta; Lorena Machi-Lara; María-Lourdes Aldana-Madrid; Josafat-Marina Ezquerra-Brauer; Ramón Robles-Zepeda; Armando Burgos-Hernandez
Journal:  Mar Drugs       Date:  2010-11-08       Impact factor: 5.118

2.  Bioactive Lipidic Extracts from Octopus (Paraoctopus limaculatus): Antimutagenicity and Antiproliferative Studies.

Authors:  Carolina Moreno-Félix; Griselda Wilson-Sánchez; Susana-Gabriela Cruz-Ramírez; Carlos Velázquez-Contreras; Maribel Plascencia-Jatomea; Ana Acosta; Lorena Machi-Lara; María-Lourdes Aldana-Madrid; Josafat-Marina Ezquerra-Brauer; Fernando Rocha-Alonzo; Armando Burgos-Hernández
Journal:  Evid Based Complement Alternat Med       Date:  2013-01-16       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.